A money day. Four separate figures worth holding in your head at once, and they are all pointing the same direction.
Anthropic Commits $11.6B to Akamai - for CPUs
Seven years, $11.6 billion, expandable by a further $9 billion to a ceiling near $20 billion. Akamai stock rose more than 20%. Anthropic takes a warrant for up to 5% of Akamai common stock - about 7.7 million shares at $111.33 - with roughly 2% vesting immediately and about 1% more per additional $3 billion purchased.
The detail most coverage skipped: this is CPU capacity, not GPU. Akamai expects to spend around $5.5 billion in capex to service it, including $1.7 billion in 2026 partly on pre-purchasing memory.
Why a CPU deal says more than the number does
AI Scribes Added $942M to Health Costs
The Blue Cross Blue Shield Association - 31 insurers, 100+ million members - attributed $942 million in added cost to AI-assisted documentation against a 2023 baseline, $653 million of it from secondary diagnoses in 2024-2025.
Among bowel surgery patients, partial intestinal blockage diagnoses rose 55% and excess acid diagnoses 33%. Anemia diagnoses rose; blood transfusions did not. BCBSA's Luke Chalker: "AI is identifying more billable conditions, not sicker patients."
The mechanism, and the caveats an insurer study deserves
Brookings: $10.3 Trillion Through 2032
Brookings projects AI infrastructure investment of $10.3 trillion between 2025 and 2032, averaging 3.6% of GDP annually - which it describes as the largest single-industry buildout as a share of GDP in US history.
Put next to the Akamai deal, the shape is consistent: capacity is being committed years in advance, at a scale that assumes demand nobody has yet demonstrated.
DeepSeek at $1B ARR, Targeting $7.5B
DeepSeek reports annual recurring revenue of $1 billion, up from under $500 million, and is targeting roughly $7.5 billion (50 billion yuan) through a Shanghai listing at a valuation near 500 billion yuan.
Worth pairing with the other DeepSeek number: API pricing rose 2.3x to 4.5x last month. The company that built its reputation on being cheap has raised prices substantially and doubled revenue. Cheap was the customer acquisition strategy, not the business model.
OpenEvidence Raises $250M at $15B
Up 25% from January's $12 billion mark. The clinical reference tool reports roughly $300 million annualised revenue and says it is used by about 40% of US physicians.
Two healthcare AI stories in one day, running in opposite directions: one tool insurers say is inflating bills, another that doctors are adopting at remarkable speed. Both are true.
Also Today
- Alibaba cut Qwen Audio 3.1 pricing hard - TTS down roughly 70%, Realtime around 85%, ASR by up to 95%, alongside new TTS-Next and ASR-Next models with speaker identification.
- TypeSafe is raising $1B+ at a $10B+ valuation, a 50x jump from its $200 million seed. Its Jev product reportedly reached 13% of Vercel paid teams within 24 hours of launch.
- Google Gemini 3.8 Live is generally available in Gemini Enterprise with avatar lip-syncing across 97 languages, and "Call for Me" has arrived for Pixel 11 users on a paid Gemini subscription.
The Through-Line
$11.6 billion committed seven years out. $10.3 trillion projected through 2032. Memory pre-purchased in 2026 for capacity nobody is using yet. And a price war where the cheapest provider just raised prices 4.5x once it had the customers.
The capability news has been loud this week. The money news is quieter and says something more specific: the people closest to this are buying capacity years ahead of the demand, and the ones who won on price are no longer competing on it.
What To Do About It This Week
- Re-check your DeepSeek costs. A 2.3x to 4.5x price rise last month is not a rounding error, and it may have moved your cheapest option.
- Budget agents as compute, not just tokens. An $11.6 billion CPU commitment is the frontier telling you the orchestration bill is real.
- If you run AI against anything that triggers a payment, read the Blue Cross piece as a template, not a healthcare story.
Sources